Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H36N6O3 |
| Molecular Weight | 492.6131 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C=C2C(NCCN3CCOCC3)=NC(=NC2=C1)C4=CC=C(C=C4)N5CCN(C)CC5
InChI
InChIKey=TUOZJWZCVIRDKO-UHFFFAOYSA-N
InChI=1S/C27H36N6O3/c1-31-10-12-33(13-11-31)21-6-4-20(5-7-21)26-29-23-19-25(35-3)24(34-2)18-22(23)27(30-26)28-8-9-32-14-16-36-17-15-32/h4-7,18-19H,8-17H2,1-3H3,(H,28,29,30)
| Molecular Formula | C27H36N6O3 |
| Molecular Weight | 492.6131 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CPG-52364 is a potent antagonist of toll-like receptors TLR7, TLR8, TLR9. The drug was developed by Coley Pharmaceutical Group (later acquired by Pfizer) for the treatment of immune diseases and reached phase I of clinical trials presumably for systemic lupus erythematosus. However, the development of CPG-52364 was terminated by unknown reason.
Originator
Approval Year
Sample Use Guides
Patienrs received 1, 3, 10, 30 or 100 mg of CPG-52364 orally as a single dose.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:40 UTC 2023
by
admin
on
Sat Dec 16 11:36:40 UTC 2023
|
| Record UNII |
5TVM84YK6F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5TVM84YK6F
Created by
admin on Sat Dec 16 11:36:40 UTC 2023 , Edited by admin on Sat Dec 16 11:36:40 UTC 2023
|
PRIMARY | |||
|
CPG-52364
Created by
admin on Sat Dec 16 11:36:40 UTC 2023 , Edited by admin on Sat Dec 16 11:36:40 UTC 2023
|
PRIMARY | Description: CPG-52364 a small molecule TLR7/8/9 antagonist, has recently completed phase 1 clinical trial for SLE therapy. Toll-like receptors (TLRs) are a family of type I transmembrane receptors and the central components of the innate immune system. Human TLR3, TLR7, TLR8, and TLR9 are expressed on endosomal membranes in the cells and recognize pathogenderived nucleic acid molecular patterns.5 However, recognition of endogenous immune complexes containing self-nucleic acids as PAMPs or DAMPs contributes to certain autoimmune diseases, such as systemic lupus erythematosus (SLE), psoriasis,7 arthritis, and multiple sclerosis.8 Therefore, inhibition of these recognition signals is expected to have therapeutic value. (last updated: 11/11/2015). | ||
|
25105690
Created by
admin on Sat Dec 16 11:36:40 UTC 2023 , Edited by admin on Sat Dec 16 11:36:40 UTC 2023
|
PRIMARY | |||
|
1093135-60-4
Created by
admin on Sat Dec 16 11:36:40 UTC 2023 , Edited by admin on Sat Dec 16 11:36:40 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Coley Pharmaceutical Group; Class: Small molecule; Mechanism of Action: Toll-like receptor 7 antagonist, Toll-like receptor 8 antagonist, Toll-like receptor 9 antagonist; Highest Development Phase: Discontinued for Systemic lupus erythematosus; Most Recent Events: 27 Jan 2010 Discontinued - Phase-I for Systemic lupus erythematosus in USA (PO), 27 Jan 2010 Discontinued - Phase-I for Systemic lupus erythematosus in USA (PO), 29 Oct 2007 Phase-I clinical trials in Systemic lupus erythematosus in USA (PO)
|
